Satellite Banner
Molecular & Clinical Diagnostics
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Bruker Announces the Appointment of Thomas Bachmann

Published: Thursday, August 22, 2013
Last Updated: Thursday, August 22, 2013
Bookmark and Share
Appointment of Mr. Bachmann as President of the Bruker BioSpin Group.

Bruker Corporation has announced the appointment of Mr. Thomas Bachmann as the new President of its Bruker BioSpin Group.

Mr. Bachmann most recently served as Chief Executive Officer of Tecan Group in Switzerland, a leading global provider of complex laboratory instrumentation and integrated liquid-handling workflow solutions for life science research and diagnostics.

The Bruker BioSpin Group is the global market and technology leader in analytical and preclinical magnetic resonance instrumentation, with major operations in Germany, Switzerland, France and the United States, as well as numerous applications and customer service centers around the world.

The Bruker BioSpin Group operates in two divisions:

• Magnetic Resonance Spectroscopy (MRS) division, consisting of the three business units nuclear magnetic resonance (NMR), electron paramagnetic resonance (EPR) and compact magnetic resonance (CMR)
• Preclinical Imaging (PCI) division, consisting of the preclinical imaging product lines magnetic resonance imaging (MRI), magnetic particle imaging (MPI), X-ray micro-CT, as well as optical and PET/SPECT/CT molecular imaging.

Frank Laukien, Bruker's President and Chief Executive Officer, stated: "I am very pleased to welcome Thomas Bachmann to Bruker. His life-science background and his broad management experience will allow him to lead our excellent BioSpin management team in order to further accelerate our innovation, profitable growth and operational excellence initiatives. Thomas will be a valuable addition for all of Bruker due to his diversified industrial experience, his global customer and operations exposure, and his successful track record."

"Bruker is a premier brand in our analytical, life-science and diagnostic instruments industry, and an exceptional company that I have come to know well over the past few years," said Thomas Bachmann. "I am delighted to join Bruker, and together with an experienced management team I look forward to further developing the Bruker BioSpin Group. With emphasis on innovation for customers, applications development and market expansion, paired with operational excellence and margin expansion, Bruker BioSpin has significant value creation potential over the years to come."

Thomas Bachmann brings over twenty-five years of global experience in sales and marketing, in leading and transforming complex businesses, as well as in strategy and business development to his new role as Bruker BioSpin Group President, including experience as a CEO of two publicly traded companies.

From 2005 until 2012, Mr. Bachmann served as CEO of Tecan Group, where he increased operational effectiveness, expanded into new businesses, developed emerging markets, created a solid organization, established regulatory competence and compliance, grew profitability and built a strong balance sheet.

From 2002 until 2004, he was CEO of the Arbonia-Forster Group's Steel Systems Business, a global provider of building supplies.

From 1985 until 2002, Mr. Bachmann served in various roles as global Sales and Marketing Director, Business Unit Director and Senior Vice President of Corporate Development at Rieter Holding, a global provider of textile machinery and plants, as well as an automotive supplier of acoustic- and thermal insulation systems.

Mr. Bachmann holds a B.Sc. in Mechanical Engineering and an Executive MBA from IMD Business School in Switzerland.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,500+ scientific posters on ePosters
  • More than 5,000+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Bruker MALDI Biotyper™ Receives CFDA Clearance
Company receives clearance from the China Food and Drug Administration to market and sell its IVD MALDI Biotyper System as a medical device in China for the identification of microorganisms isolated from human specimens.
Thursday, June 26, 2014
Bruker Reports 7% Revenue Growth in Q4
Bruker Corporation reported financial results for its fourth quarter and full year ended December 31, 2013.
Wednesday, February 19, 2014
Bruker Granted FDA Clearance to Market the MALDI Biotyper CA System
Bruker able to market MALDI Biotyper CA System in the US for the identification of Gram negative bacterial colonies cultured from human specimens.
Tuesday, November 26, 2013
Novel Approach for Inborn Errors of Metabolism Screening by NMR
Clinical IEM-by-NMR screening study in Turkey measures 65 metabolites in urine simultaneously, including 20 endogeneous metabolites and 45 metabolites associated with inborn errors of metabolism.
Wednesday, September 04, 2013
Bruker Announces Framework Agreement with Duzen
Duzen selects Bruker's MALDI Biotyper for mass spectrometry-based molecular microbial identification.
Wednesday, June 06, 2012
Scientific News
Heart Arrhythmia Caused by Mosaic of Mutant Cells
Researchers have solved the genetic mystery of an infant suffering from heart arrhythmia.
Crispr Toolbox Expanded By Protein
Researchers have shown a newly discovered CRISPR protein has two distinct RNA cutting activities.
Over Two-Thirds of Cervical Cancer Deaths Prevented
Cervical screening prevents 70% of cervical cancer deaths and if all eligible women regularly attended screening this would rise to 83%.
Detecting Bacterial Infections in Newborns
Researchers tested an alternative way to diagnose bacterial infections in infants—by analyzing RNA biosignatures from a small blood sample.
Mechanisms of Parkinson’s Pathology
Defects that lead to cells’ failure to decommission faulty mitochondria cause nerve cells to die, triggering the symptoms of Parkinson’s disease.
Case for Liquid Biopsies Builds in Advanced Lung Cancer
Study addresses unmet need for better, non-invasive tests called out in recent "Moonshot" blue ribbon panel report
Genetic Misdiagnoses of Heart Condition
Analysis found several genetic variations previously linked with a heart condition were harmless, leading to condition misdiagnosis.
Opening Door to Oesophageal Cancer Targeted Treatments
Scientists have discovered that oesophageal cancer can be classified into three different subtypes.
Genetic Diversity of Enzymes Alters Metabolic Individuality
ToMMo scientists have shown that genetic polymorphisms, structural location of mutation and effect for phenotype correlate with each other.
IMM Uses Nanowizard® to Evaluate Cardiovascular Disease Risk
JPK Instruments reports on the use of their NanoWizard® AFM system at the Instituto de Medicina Molecular at the University of Lisbon.
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,000+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!